It is made available under a CC-BY 4.0 International license .

1

1 Neonatal outcomes after proteomic biomarker-guided intervention: the AVERT

2 PRETERM TRIAL

3

- 4 Matthew K. HOFFMAN, MD, MPH¹; Carrie KITTO¹; Zugui ZHANG, PhD¹; Jing SHI²,
- 5 PhD; Michael G. WALKER², PhD; Babak SHAHBABA³, PhD; Kelly RUHSTALLER, MD
- 6 MSCE¹
- ⁷ ¹Department of Obstetrics and Gynecology, ChristianaCare, Newark, DE
- 8 ²Walker Bioscience, Carlsbad, CA
- ⁹ ³Departments of Statistics and Computer Science, University of California Irvine, Irvine,

10 CA

11

12 Conflicts of Interest

- 13 BS, JS, and MGW are paid consultants of Sera Prognostics, Inc. For the purposes of
- 14 this study, JS and MGW reported to MKH and were paid consultants of ChristianaCare,
- 15 and BS was supported by Sera Prognostics, Inc. MKH received an investigator-initiated
- 16 grant from Sera Prognostics, Inc., to conduct this study.

17

18 Source of Funding

- 19 This study was performed as an investigator-initiated trial funded by Sera Prognostics,
- 20 Inc. The funder provided testing and funds to conduct the trial. The study plan was

It is made available under a CC-BY 4.0 International license .

- 21 mutually agreed upon by the investigators and the funder; however, the funder was
- 22 blinded to study results until after data lock and analysis completion.

23

24 Corresponding Author

- 25 Matthew K. Hoffman, MD MPH
- 26 Department of Obstetrics & Gynecology
- 27 4755 Ogletown-Stanton Road
- 28 Newark, DE 19718
- 29 Telephone: +1 (302) 301-3350
- 30 Fax: +1 (302) 733-3340
- 31 Email: mhoffman@christianacare.org

It is made available under a CC-BY 4.0 International license .

32 Abstract

33 1. Background

34 Vaginal progesterone, low dose aspirin and care management (comprising increased

- 35 outreach and education) has been shown to reduce the rate of prematurity in select
- 36 populations, but identifying at-risk pregnancies has been problematic.

37 2. Objective(s)

38 Test the hypothesis that screening singleton, non-anomalous pregnancies lacking

39 traditional clinical risk factors with a validated blood test for preterm birth risk prediction,

40 then targeting those with elevated risk for preventive treatment, would improve neonatal

41 outcomes as compared to a large historical population.

42 3. Study Design

43 The AVERT PRETERM trial took place from June 2018-September 2020 at 44 ChristianaCare Hospital (Newark, DE). Singleton non-anomalous pregnancies with no 45 history of preterm birth were enrolled in a prospective study arm and followed through 46 neonatal hospital discharge. Participants were screened using a serum proteomic test 47 for spontaneous preterm birth risk during a gestational age window spanning 19^{1/7}-20^{6/7} 48 weeks. Pregnancies identified by the test to be at elevated risk for preterm birth 49 (≥16.0%, approximately twice the U.S. population risk) were offered aspirin 81 mg daily. 50 open-label vaginal progesterone 200 mg daily and care management. We compared 51 outcomes for women who screened either low-risk or higher-risk accepting treatment 52 with those in a historical study arm of 10,000 pregnancies. Our co-primary outcomes 53 were neonatal hospital length of stay and an ordinal neonatal morbidity index score

4

based on the occurrence of grade III/IV interventricular hemorrhage, necrotizing
enterocolitis (Bell stage II/III), respiratory distress syndrome, bronchopulmonary
dysplasia, retinopathy of prematurity (stage III), sepsis, and neonatal death or neonatal
intensive care unit length of stay. Cox proportional hazards survival analysis and ordinal
logistic regression were utilized to evaluate outcomes and control for population
differences.

60 4. Results

61 A total of 1463 women were screened and tested before research operations were 62 ceased due to the advent of the COVID-19 pandemic, and three women were 63 subsequently deemed ineligible after screening. Of these, 34.72% (507/1460) were 64 deemed high-risk, with 56.41% (286/507) accepting intervention and 43.59% (221/507) 65 forgoing intervention. The remaining 65.3% (953/1460) were designated as low-risk. 66 Women in the prospective arm were older, more obese, more likely to have 67 hypertension and smoke, and less likely to use opioids compared to women in the 68 historical arm. The primary analyses found that neonates in the prospective arm were 69 discharged from the hospital earlier (P=0.01; hazard ratio, 1.35; 95% confidence 70 interval, 1.08-1.70) and had lower neonatal morbidity index scores (P=0.031; odds ratio, 71 0.81; 95% confidence interval, 0.67-0.98). Average neonatal hospital length of stay 72 decreased by 21%, and severe neonatal morbidity (neonatal morbidity index \geq 3) was 73 reduced on average by 18%.

74 5. Conclusions

75	Identifying singleton, non-anomalous pregnancies lacking traditional risk factors with a
76	validated proteomic blood test for preterm birth risk and providing treatment to those at
77	risk resulted in improved neonatal outcomes compared to controls in a racially diverse
78	cohort. This test-and-treatment strategy shows promise for ameliorating the impacts of
79	premature birth among individuals in this previously unidentified patient population.
80	

81 Keywords

- 82 Care management, low-dose aspirin, neonatal morbidity index, NICU length of stay,
- 83 pregnancy, preterm birth, proteomic biomarker, risk stratification, spontaneous preterm
- 84 birth, vaginal progesterone

85 Introduction

86 Preterm birth (PTB) remains the leading cause of perinatal mortality,^{1,2} and children born prematurely are at greater risk for chronic medical conditions^{3,4} and 87 88 developmental delays.⁵ These risks are inversely proportional to the neonate's 89 gestational age (GA) at birth.⁶ Improvements in survival are largely attributable to the use of improved neonatal care⁷ and antenatal corticosteroids.⁸ Strategies targeting at-90 91 risk women, such as focused care management⁹ (comprising increased outreach and education) along with low-dose aspirin (LDASA),¹⁰ and vaginal progesterone^{11,12} have 92 93 demonstrated reductions in PTB, but their impact has been limited by poor precision in 94 identifying at-risk pregnancies. Shortened cervical length measured by transvaginal 95 sonography in the second trimester has been shown to predict the risk of preterm 96 delivery.¹³ With vaginal progesterone treatment, the PTB rate <34 weeks' gestation is 97 decreased by approximately 45%, but the rate of PTB <37 weeks' gestation is 98 unchanged.¹⁴ The utility of this strategy is blunted by the limited ability of cervical 99 sonography to identify women who will deliver preterm, with most women delivering 100 prematurely not having a short cervix at the time of routine sonography.^{15,16} Similarly, 101 LDASA has been shown to decrease PTB incidence and severity^{17,18} but generally has 102 been recommended for pregnancies at risk for preeclampsia.¹⁹ Finally, care 103 management of higher-risk pregnancies has been shown to decrease PTB; historically, 104 however, its use has targeted pregnancies with known PTB risk factors,^{9,20} which are 105 frequently absent in those who deliver prematurely.

106 Recently, novel discoveries in proteomics have come to identify and validate107 proteins that are differentially expressed in pregnancies that deliver prematurely

7

108	compared to term births. One validated spontaneous PTB (sPTB) predictor, which
109	evaluates the ratio of serum insulin-like growth factor binding protein 4 (IGFBP4) to sex
110	hormone-binding globulin (SHBG) in the window of 19 ^{1/7} -20 ^{6/7} weeks' gestation,
111	stratified risk in U.S. women with a precision (area under the receiver operating
112	characteristic curve [AUC]) of 0.80.21 A risk score threshold corresponding to twice the
113	U.S. population PTB risk was subsequently validated ²² and shown to significantly
114	stratify higher- and lower-risk subjects for an extended blood draw window of 180/7-206/7
115	weeks' gestation.
116	Nonetheless, the question of whether targeting treatment can improve neonatal
117	outcomes for women indicated by the test to be at increased risk for preterm delivery
118	but who lack traditional clinical risk factors remains largely uninvestigated. The purpose
119	of the AVERT PRETERM trial was to test the hypothesis that screening singleton non-
120	anomalous pregnancies with a validated blood test for PTB risk prediction, and then
121	treating higher-risk pregnancies with care management, LDASA, and vaginal
122	progesterone, would improve neonatal outcomes compared to a large historical
123	population.
124	

The AVERT PRETERM trial was conducted from June 2018-September 2020 at
ChristianaCare Hospital, a regional health care system based in Newark, DE.
ChristianaCare serves a mixed urban and rural population across Delaware and

129 Maryland.

Materials and Methods

125

It is made available under a CC-BY 4.0 International license .

8

130

131 Trial Oversight

The study protocol (NCT03151330) was approved by the ChristianaCare institutional review board prior to participant enrollment. An independent data safety monitoring board convened prior to study initiation, approved the protocol, and provided oversight of adverse events. All subjects provided written informed consent to participate in the study. The listed authors accept responsibility for the accuracy and completeness of the data and for fidelity in the conduct of the trial.

138 In April 2020, all non-COVID research was halted at ChristianaCare Health 139 System, and the decision was made to terminate the trial and reassess the analytic plan 140 in a blinded fashion. In July 2020, an investigation²³ showed that COVID-19 infection led 141 to an increase in prematurity. To avoid bias in comparison of pre-pandemic controls to 142 prospective subjects who reached term during the pandemic period, we modified the 143 statistical analysis plan (SAP), while blinded, by limiting the primary analysis to subjects 144 who had reached 37 weeks' gestation before the local spread of SARS-CoV-2 and the 145 associated research shutdown.

146

147 Screening and Recruitment

Two separate study arms were defined, both of which comprised singleton pregnancies
without ultrasound evidence of mullerian or fetal anomalies, cervical shortening (<25
mm), genetic anomalies, history of a prior PTB, cervical cerclage or medical conditions
with clear indication for PTB <37 weeks' gestation. Pregnancies in the prospective arm

9

were identified and screened for eligibility in ambulatory sites and/or at the time of routine imaging ultrasound. Due to the requirements of the proteomic blood test for prematurity (PreTRM), women in the prospective arm were excluded if they had a blood transfusion during the current pregnancy, known hyperbilirubinemia, or were taking traditional or low molecular weight heparin. Similarly, prospective patients were excluded if they had a known reaction or contraindication to progesterone or aspirin.

158

159 Procedures

160 Following consent, blood was obtained from women in the prospective arm during the 161 window of 19^{1/7}-20^{6/7} weeks' gestation. Samples were processed, shipped, stored, and 162 analyzed using the PreTRM test in a Clinical Laboratory Improvement Amendments-163 and College of American Pathologists-certified laboratory (Sera Prognostics, Inc., Salt 164 Lake City, UT), as described previously.^{21,24} Test results were shared with the 165 participant and her care provider. Pregnancies with a sPTB risk score ≥16.0% 166 (approximately twice the U.S. population risk) were then offered and consented again to 167 receive care management, consisting of twice-weekly nursing contacts to monitor 168 medication compliance and symptom development, aspirin 81 mg daily, and 169 progesterone 200 mg intravaginally daily. The remainder of care was determined by the 170 treating clinician. Outcomes for both study arms were obtained through a validated 171 obstetrical registry²⁵ or, for patients in the prospective arm who delivered at another 172 institution, through review of individual medical records. External data review was 173 performed for all prospective patients in addition to 10% of the historical arm to ensure 174 that eligibility requirements were met. An error rate of <3% was deemed acceptable. All

10

PTB cases in both arms were reviewed further for accurate assessment of primary
outcomes by a single investigator (MKH). Additionally, because secular changes in care
might affect outcomes in a non-random fashion amongst women in the prospective arm,
major changes in guidance or management protocols were documented on a quarterly
basis.

180

181 Trial Outcomes

182 Two co-primary outcomes were selected, the first being neonatal hospital length of stay 183 (NNLOS). Because of the competing risk of death resulting in shorter stays, we set the 184 NNLOS for fetuses or newborns who expired to be one day longer than the longest 185 neonatal stay observed among all neonates. The second co-primary outcome was 186 based on a neonatal morbidity index (NMI)¹⁴ composed of the following components: 187 grade III/IV intraventricular hemorrhage, necrotizing enterocolitis (Bell stage II/III), 188 respiratory distress, bronchopulmonary dysplasia (need for oxygen at 28 days of life or 189 36 weeks post-conceptional age), retinopathy of prematurity (stage III), proven sepsis 190 (positive blood cultures) and postnatal death. To provide severity estimates, NMI 191 scoring was organized as follows: 0, no events; 1, one event or neonatal intensive care 192 unit (NICU) admission <5 days with no perinatal mortality; 2, two events or five to 20 193 days of NICU admission with no perinatal mortality; 3, three events or >20 days in the 194 NICU without perinatal mortality; and 4, perinatal mortality.

195

196 **Power and Sample Size Analysis**

11

At termination, 1873 eligible subjects had been enrolled in the prospective arm, with
1460 reaching 37 weeks' gestation prior to the first reported COVID-19 case in
Delaware. A total of 10000 consecutive historical controls who met the same eligibility
criteria were selected from an approximately two-year period immediately prior to study
initiation.

202 From institutional data on pregnancies at ChristianaCare, we estimated a 203 historical PTB rate of 9.1%. Sample size estimation was based on simulations of the co-204 primary outcomes using a simulated GA distribution with a singleton PTB rate of 9.1% 205 and an effect of intervention based on existing literature. α -level spending of 0.05 was 206 shared between co-primaries using Holm's method.

For the first co-primary outcome, the proportion of subjects with NMI scores \geq 3 was assumed to be 2.0-2.3% in the prospective arm and near 3.6% in the control arm, based on a previous clinical utility study.²⁶ Assuming these proportions and a one-sided Fisher's Exact test, a sample size of approximately 1453 subjects with outcomes in the prospective arm with 55% compliance among higher-risk subjects, and approximately 10000 historical controls, would provide power of 0.7-0.9.²⁷

For the second co-primary outcome, NNLOS from time of birth up to discharge, the hazard ratio (HR) based on simulations was expected to be 1.32-1.46, based on the previously referenced clinical utility study.²⁶ Assuming these HRs, a sample size of approximately 1453 subjects with outcomes in the prospective arm with 55% compliance among higher-risk subjects and approximately 10000 historical controls, would provide power of at least 0.8.²⁷

It is made available under a CC-BY 4.0 International license .

12

219

220 Statistical Analysis

221	Descriptive statistics were used to describe all data. Variables were summarized using
222	means and standard deviations for continuous data, and percentages and frequencies
223	for categorical data. Comparisons for baseline characteristics were performed; the
224	Wilcoxon rank sum test was used to compare continuous variables between two
225	groups, and contingency table analysis (chi-square) was used to compare categorical
226	variables. In comparisons, differences with <i>P</i> <0.05 were considered significant.
227	The first co-primary hypothesis, reduction in severe composite NMI scores, was
228	tested using ordinal logistic regression, adjusted by covariates. The second co-primary
229	hypothesis, reduction in neonatal length of stay, and the two co-secondary hypotheses,
230	reduction in NICU length of stay (NICULOS) and increase in GA at birth (GAB), were all
231	tested using Cox proportional hazards regression, adjusted by covariates.
232	The co-primary and co-secondary analyses used a modified intent-to-treat
233	population, defined as all subjects for whom both co-primary outcomes were known;
234	and who were either selected for the historical control arm, received a low-risk PreTRM
235	test result, or consented to and initiated treatment with vaginal progesterone and
236	LDASA <24 weeks' gestation after receiving a higher-risk PreTRM test result.
237	As prespecified by a selection procedure defined in the SAP, subjects in the
238	highest 8.5% quantile of each arm were included in the NICULOS and NNLOS
239	analyses, while subjects in the lowest 8.5% quantile of each arm were included in the
240	GAB analysis. Specifically, 8.5% was selected to be 1.2 times the PTB rate of the

It is made available under a CC-BY 4.0 International license .

historical control arm (7.1%). This was done to examine outcomes at the extremes of
PTB rather than capturing short NICU stays for conditions that tend to dominate NICU
admissions, including transient tachypnea of the newborn, hypoglycemia and
temperature instability.

As prespecified in the SAP, the covariates included in the models for the primary and secondary analyses were maternal age, parity and maternal substance use disorders, assessed as Neonatal Opioid Withdrawal Syndrome. Additional covariates were examined in sensitivity analyses.

Differences between the treatment arms in the proportion of each treatment group at each NMI level were calculated using the fitted ordinal logistic regression model with the covariates maternal age, parity and maternal substance use disorders. Percent differences between the treatment arms for time to event analyses were calculated using the hazard rate for each group as estimated by the fitted Cox proportional hazards model with the covariates maternal age, parity and maternal substance use disorders.

The proportional odds assumption for the effect of treatment arm in the ordinal logistic regression was examined and found not to be violated. The proportional hazards assumption for treatment arm in the Cox regression analyses was tested and found not to be violated.

Analyses were performed using R software version 4.2.2.³² Two-tailed *P*-values <0.05 were considered significant. Holm's multiple comparisons correction was used for the co-primary hypotheses.

It is made available under a CC-BY 4.0 International license .

263

264 **Results**

- At study termination, 1873 eligible subjects had been enrolled in the prospective arm,
- 266 1463 of whom aligned with pre-COVID-19 patient care conditions and were screened
- with the PreTRM test (Figure 1). Of these, 34.7% (507/1463) were deemed higher risk
- by the PreTRM test. Among the screened population, 83.3% (1218/1463) had clinical
- outcomes and qualified either as low-risk (77.1%; 939/1218) or as higher-risk accepting
- 270 treatment (22.9%; 279/1218).

271 Baseline participant characteristics and delivery data are shown in **Table 1**. The 272 prospective arm was noted to be significantly older, more obese, less likely to be 273 nulliparous, and more likely to have hypertension and smoke than historical controls. 274 Similarly, body mass index was higher in the prospective arm compared to historical 275 controls – mostly due to higher weight, though the prospective arm was nominally taller 276 than historical controls. The proportion of Black women in both arms was 26.5%, 277 reflecting the racial diversity in the study site's patient population. Three women 278 reported stopping vaginal progesterone due to adverse effects, and one woman 279 discontinued LDASA.

Results of hypothesis tests for the co-primary and co-secondary outcomes are presented in **Table 2**. NNLOS was significantly reduced in the prospective arm vs the historical arm (HR 1.35; 95% CI, 1.08-1.7; P=0.01). The Kaplan-Meier plot for NNLOS is shown in **Figure 2**, reflecting a reduction of mean NNLOS of 21% (Cox proportional hazard [PH] P = 0.01). NMI scores were significantly reduced in the prospective arm vs

15

285	the historical arm (OR 0.81; 95% CI 0.67-0.98; <i>P</i> =0.03), indicating more favorable
286	outcomes for the prospective arm (Table 2). Specifically, the probability of NMI \geq 1 (any
287	impairment) or NMI ≥3 (severe NMI) was reduced on average approximately by 13%-
288	17% or 18%, respectively, across a range of co-variate values (Supplemental Table 1).
289	After achieving statistical significance for both co-primary endpoints per the SAP,
290	we proceeded to test the two co-secondary hypotheses. In Cox regression analysis,
291	children tended to leave the NICU earlier (HR 1.2; 95%CI, 0.96-1.51), but this difference
292	was not significant (<i>P</i> =0.12). No differences in overall weeks' gestation was noted
293	(<i>P</i> =0.584, HR 0.962).
294	In a non-prespecified analysis, we noted that although there was no difference in overall
295	GA at delivery, there was a difference in the number of pregnancies that delivered <32
296	weeks' gestation (HR, 0.52; 95%Cl, 0.28-0.94; Cox PH <i>P</i> =0.009) (Figure 3),
297	corresponding to an extension of mean gestation for births <32 weeks of 2.5 weeks
298	(mean of 27.46 and 29.93 weeks for historical and prospective arms, respectively).
299	Figure 4 shows a Kaplan-Meier plot for neonatal hospital stay among babies born <32
300	weeks. Neonates left the hospital earlier in the prospective arm than the historical arm
301	(HR, 1.84, 95% CI 1.01-3.36, Cox PH <i>P</i> =0.046) with differences in mean stays of
302	approximately 30% (mean of 97.23 and 68.47 days for historical and prospective arms,
303	respectively).This suggests that an increase in pregnancy duration amongst births <32
304	weeks in the prospective arm was associated with shorter neonatal hospital stay.
305	Finally, in an exploratory analysis of all subjects (not only the 8.5%ile specified in
306	the primary analysis) NNOLOS was reduced by 16% (mean of 5.1 and 4.28 days, HR:
307	1.15, 95%CI, 1.08-1.22, <i>P</i> <0.001) and 17% (mean 3.95 and 3.27 days, HR 1.15, 95%

It is made available under a CC-BY 4.0 International license .

16

- 308 CI, 1.08-1.22, *P*<0.001), with and without the adjustment for neonatal death,
- 309 respectively.
- 310
- 311 Comment
- 312 Principal Findings
- 313 The results of this trial demonstrate that women who were screened and stratified with a
- 314 proteomic test for PTB risk, and were treated with care management, LDASA, and
- 315 vaginal progesterone, had shorter NNLOS and less severe neonatal morbidities
- 316 compared to a large historical arm, after controlling for population differences.

317

318 **Results in the Context of What is Known**

- Historically, evidence has existed for the benefit of intervening on pregnant women stratified by clinical risk factors. These data suggest that proteomic biomarker-based stratification and focused intervention may improve outcomes in otherwise low-risk women.
- 323

324 Clinical Implications

These findings suggest a potential approach for universal screening and treatment to help ameliorate complications of PTB amongst women who lack traditional risk factors for preterm delivery. The results of this study resonate with an investigation³³ that randomized 1,191 women to either knowing and receiving treatment vs not knowing the

17

329 results of their screening test. In that study, the NICU length of stay due to sPTB was 330 significantly less amongst those screened and treated vs. those not receiving their test 331 results (median 6.8 days vs. 45.5 days; P=0.005), though the study was limited by small 332 numbers. We note that similar strategies of both evaluating prior pregnancy for PTB 333 and/or routine cervical length have been widely accepted in many centers,^{28,29} but this 334 strategy captures a limited number of PTBs, and pregnancy history is not relevant for 335 the first-time mothers who represent a sizable portion of the population. 336 Given the notable increase in PTB rate among Black women (14.4%) as 337 compared to the U.S. population as a whole (10.2%),² it is important to note that Black participants were represented in the AVERT PRETERM prospective and historical arms 338 339 with a proportion (26.5%) nearly double recent U.S. population estimates (13.6%).³⁰ The 340 results in this study population, along with those in two large and similarly diverse 341 studies,^{21,31} indicate that the PreTRM test will be applicable across the diverse U.S. 342 population.

343

344 **Research Implications**

Patient knowledge of preterm birth risk via validated proteomic testing may offer an opportunity to combine a novel risk assessment with strategies proven to be effective with clinical risk factors. Based on survey data, pregnant women are frequently resistant to taking medication due to perceived deleterious effects during pregnancy. Prospective trials randomizing women to being informed of results with clinical treatment vs testing with blinded results have begun and will provide more definitive evidence.

It is made available under a CC-BY 4.0 International license .

18

351

352 Strengths and Limitations

Strengths of the trial include a multimodal strategy incorporating interventions that have consistently shown benefit in reducing the impacts of prematurity, as well as a novel proteomic blood test that has been validated in multiple cohorts. Additionally, we note that the dataset used to obtain the historical controls has been well validated, and all cases of PTB were reviewed. Clinically, the impact appears to be greatest amongst pregnancies delivering <34 weeks' gestation, which remains the primary driver of newborn and child morbidity and mortality.

360 Limitations of the study are inherent in the design of comparing a prospective 361 arm that differed from the historical arm in several maternal demographic and medical 362 conditions. These were addressed through multivariable modeling, but we note that this 363 remains a potential source of bias. Even so, significant demographic differences in the 364 prospective arm vs the historical arm – older age, more hypertension and more smoking 365 - likely biases the prospective arm toward increased PTB incidence, further underscoring the importance of our findings. Additionally, at least for the use of LDASA. 366 367 guideline changes have expanded the number of women eligible for treatment, and a 368 recent estimate suggests that most pregnancies should be counseled about LDASA.³⁸. 369 Finally, we note some overlap of our co-primary outcomes, as NICULOS was also part 370 of the NMI.

371

372 Conclusions

It is made available under a CC-BY 4.0 International license .

- 373 In summary, (1) screening singleton, non-anomalous pregnancies lacking traditional
- 374 clinical risk factors with a validated proteomic blood test for preterm birth prediction,
- then (2) targeting those with elevated risk for preventive treatment, improved neonatal
- 376 outcomes as compared to a large historical population. This test-and-treatment strategy
- 377 led to shorter hospital stays and improved NMI scores across a diverse population.
- 378

379 Acknowledgements

- 380 We wish to acknowledge the funding provided by Sera Prognostics, Inc., to conduct this
- independent investigation. Jennifer Logan, PhD, an employee of Sera Prognostics, Inc.,
- 382 provided medical writing support for the manuscript.

383 References

- 1. Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5
- 385 mortality in 2000-15: an updated systematic analysis with implications for the
- 386 Sustainable Development Goals. Lancet 2016;388(10063):3027-3035. DOI:
- 387 10.1016/S0140-6736(16)31593-8.
- 388 2. Osterman MJK, Hamilton BE, Martin, J.A., Driscoll AKV, C.P. Births: Final Data
- for 2020. Division of Vital Statistics, National Center for Health Statistics, U.S.
- 390 Centers for Disease Control and Prevention. 2022 Feb 7. Available at
- 391 <u>https://www.cdc.gov/nchs/nvss/births.htm</u>. Accessed February 9, 2022.
- 392 3. Moster D, Lie RT, Markestad T. Long-term medical and social consequences of
- 393 preterm birth. N Engl J Med 2008;359(3):262-73. DOI:
- 394 10.1056/NEJMoa0706475.
- 395 4. Crump C, Sundquist K, Sundquist J, Winkleby MA. Gestational age at birth and
 396 mortality in young adulthood. JAMA 2011;306(11):1233-40. DOI:
- 397 10.1001/jama.2011.1331.
- 398 5. Sun BZ, Moster D, Harmon QE, Wilcox AJ. Association of Preeclampsia in Term
- 399 Births With Neurodevelopmental Disorders in Offspring. JAMA Psychiatry

400 2020;77(8):823-829. DOI: 10.1001/jamapsychiatry.2020.0306.

- 401 6. Tyson JE, Parikh NA, Langer J, Green C, Higgins RD, National Institute of Child
- 402 H, Human Development Neonatal Research N. Intensive care for extreme
- 403 prematurity--moving beyond gestational age. N Engl J Med 2008;358(16):1672-
- 404 81. DOI: 10.1056/NEJMoa073059.

- 405 7. Richardson DK, Gray JE, Gortmaker SL, Goldmann DA, Pursley DM, McCormick
- 406 MC. Declining severity adjusted mortality: evidence of improving neonatal
- 407 intensive care. Pediatrics 1998;102(4 Pt 1):893-9. DOI: 10.1542/peds.102.4.893.
- 408 8. Crowley PA. Antenatal corticosteroid therapy: a meta-analysis of the randomized
- 409 trials, 1972 to 1994. Am J Obstet Gynecol 1995;173(1):322-35. DOI:
- 410 10.1016/0002-9378(95)90222-8.
- 411 9. Garite TJ, Manuck TA. Should case management be considered a component of
- 412 obstetrical interventions for pregnancies at risk of preterm birth? Am J Obstet

413 Gynecol 2023;228(4):430-437. DOI: 10.1016/j.ajog.2022.09.022.

- 414 10. Hoffman MK, Goudar SS, Kodkany BS, et al. Low-dose aspirin for the prevention
- 415 of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN):
- 416 a randomised, double-blind, placebo-controlled trial. Lancet

417 2020;395(10220):285-293. DOI: 10.1016/S0140-6736(19)32973-3.

- 418 11. Hassan SS, Romero R, Vidyadhari D, et al. Vaginal progesterone reduces the
- 419 rate of preterm birth in women with a sonographic short cervix: a multicenter,
- 420 randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol
- 421 2011;38(1):18-31. DOI: 10.1002/uog.9017.
- 422 12. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH, Fetal Medicine
- 423 Foundation Second Trimester Screening G. Progesterone and the risk of preterm
- 424 birth among women with a short cervix. N Engl J Med 2007;357(5):462-9. DOI:
- 425 10.1056/NEJMoa067815.
- 426 13. Iams JD, Goldenberg RL, Meis PJ, et al. The length of the cervix and the risk of
 427 spontaneous premature delivery. National Institute of Child Health and Human

It is made available under a CC-BY 4.0 International license .

428	Development	Maternal Fetal Medicine	Unit Network. N Engl J Med
-----	-------------	-------------------------	----------------------------

- 429 1996;334(9):567-72. DOI: 10.1056/NEJM199602293340904.
- 430 14. Cahill AG, Odibo AO, Caughey AB, Stamilio DM, Hassan SS, Macones GA,
- 431 Romero R. Universal cervical length screening and treatment with vaginal
- 432 progesterone to prevent preterm birth: a decision and economic analysis. Am J
- 433 Obstet Gynecol 2010;202(6):548 e1-8. DOI: 10.1016/j.ajog.2009.12.005.
- 434 15. Esplin MS, Elovitz MA, lams JD, et al. Predictive Accuracy of Serial Transvaginal
- 435 Cervical Lengths and Quantitative Vaginal Fetal Fibronectin Levels for
- 436 Spontaneous Preterm Birth Among Nulliparous Women. Jama
- 437 2017;317(10):1047-1056. DOI: 10.1001/jama.2017.1373.
- 438 16. Berghella V, Saccone G. Cervical assessment by ultrasound for preventing
- 439 preterm delivery. Cochrane Database Syst Rev 2019;9(9):CD007235. DOI:
- 440 10.1002/14651858.CD007235.pub4.
- 441 17. Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for
- 442 preventing pre-eclampsia and its complications. Cochrane Database Syst Rev

443 2019;2019(10). DOI: 10.1002/14651858.CD004659.pub3.

- 444 18. Low dose aspirin in pregnancy and early childhood development: follow up of the
- 445 collaborative low dose aspirin study in pregnancy. CLASP collaborative group. Br
- 446 J Obstet Gynaecol 1995;102(11):861-8. DOI: 10.1111/j.1471-
- 447 0528.1995.tb10872.x.
- 448 19. Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N. Aspirin Use to
- 449 Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence

It is made available under a CC-BY 4.0 International license .

450		Report and Systematic Review for the US Preventive Services Task Force.
451		JAMA 2021;326(12):1192-1206. DOI: 10.1001/jama.2021.8551.
452	20.	Newman RB, Sullivan SA, Menard MK, Rittenberg CS, Rowland AK, Korte JE,
453		Kirby H. South Carolina Partners for Preterm Birth Prevention: a regional
454		perinatal initiative for the reduction of premature birth in a Medicaid population.
455		Am J Obstet Gynecol 2008;199(4):393 e1-8. DOI: 10.1016/j.ajog.2008.07.047.
456	21.	Saade GR, Boggess KA, Sullivan SA, et al. Development and validation of a
457		spontaneous preterm delivery predictor in asymptomatic women. Am J Obstet
458		Gynecol 2016;214(5):633 e1-633 e24. DOI: 10.1016/j.ajog.2016.02.001.
459	22.	Burchard J, Polpitiya AD, Fox AC, et al. Clinical Validation of a Proteomic
460		Biomarker Threshold for Increased Risk of Spontaneous Preterm Birth and
461		Associated Clinical Outcomes: A Replication Study. J Clin Med
462		2021;10(21):5088. DOI: 10.3390/jcm10215088.
463	23.	Khalil A, von Dadelszen P, Draycott T, Ugwumadu A, O'Brien P, Magee L.
464		Change in the Incidence of Stillbirth and Preterm Delivery During the COVID-19
465		Pandemic. JAMA 2020;324(7):705-6. DOI: 10.1001/jama.2020.12746.
466	24.	Bradford C, Severinsen R, Pugmire T, et al. Analytical validation of protein
467		biomarkers for risk of spontaneous preterm birth. Clinical Mass Spectrometry
468		2017;3:25-38. DOI: 10.1016/j.clinms.2017.06.002.
469	25.	Zhang J, Troendle J, Reddy UM, et al. Contemporary cesarean delivery practice
470		in the United States. Am J Obstet Gynecol 2010;203(4):326 e1-326 e10. DOI:
471		10.1016/j.ajog.2010.06.058.

- 472 26. Branch DW, VanBuren JM, Porter TF, et al. Prediction and Prevention of Preterm
- 473 Birth: A Prospective, Randomized Intervention Trial. Am J Perinatol 2021. DOI:
- 474 10.1055/s-0041-1732339.
- 475 27. NCSS Statistical Software. Group-Sequential Analysis for Two Proportions.
- 476 Available at <u>https://www.ncss.com/wp-</u>
- 477 <u>content/themes/ncss/pdf/Procedures/NCSS/Group-</u>
- 478 <u>Sequential Analysis for Two Proportions.pdf</u>. Accessed May 1, 2023.
- 479 28. Son M, Grobman WA, Ayala NK, Miller ES. A universal mid-trimester
- 480 transvaginal cervical length screening program and its associated reduced
- 481 preterm birth rate. Am J Obstet Gynecol 2016;214(3):365 e1-5. DOI:
- 482 10.1016/j.ajog.2015.12.020.
- 483 29. Werner EF, Hamel MS, Orzechowski K, Berghella V, Thung SF. Cost-
- 484 effectiveness of transvaginal ultrasound cervical length screening in singletons
- 485 without a prior preterm birth: an update. Am J Obstet Gynecol 2015;213(4):554
- 486 e1-6. DOI: 10.1016/j.ajog.2015.06.020.
- 487 30. U.S. Census Bureau. Quick Facts. Available at
- 488 https://www.census.gov/quickfacts/fact/table/US/PST045222. Accessed July 18,
- 489 2023.
- 490 31. Markenson GR, Saade GR, Laurent LC, et al. Performance of a proteomic
- 491 preterm delivery predictor in a large independent prospective cohort. Am J
- 492 Obstet Gynecol MFM 2020;2(3):100140. DOI: 10.1016/j.ajogmf.2020.100140.
- 493

494 **Table 1. Baseline characteristics and delivery data**

			Prospective	Prospective (higher risk accepting	<i>P</i> -value (prospective
	Historical	Prospective	(low risk)	treatment)	vs historical) [†]
N	10000	1218	939	279	0.001
Age	10000	1010		070	<0.001
N (OD)	10000	1218	939	279	
Mean (SD)	29.6 (5.4)	30.5 (5.7)	30.5 (5.6)	30.5 (5.9)	0.001
Gravida					<0.001
N	9954	1135	874	261	
Mean (SD)	2.7 (1.7)	2.41 (1.5)	2.45 (1.6)	2.27 (1.4)	
Parity					<0.001
N	9953	1159	893	266	
Mean (SD)	1.1 (1.2)	0.9 (1.1)	0.9 (1.1)	0.7 (1.0)	
Percent nulliparous [N, (%)]	6544 (65.7)	630 (54.4)	507 (56.8)	123 (46.2)	<0.001
Number of miscarriages					0.25
N	9953	1130	870	260	
Mean (SD)	1.6 (1.1)	1.6 (1.0)	1.6 (1.0)	1.6 (0.9)	
Race [‡] [N, (%)]					<0.001
American Indian	21 (0.2)	1 (0.1)	0 (0.0)	1 (0.4)	
Asian	783 (7.8)	76 (6.3)	55 (5.9)	21 (7.6)	
Black	2653 (26.5)	322 (26.5)	259 (27.7)	63 (22.7)	
Other	909 (9.1)	74 (6.1)	53 (5.7)	21 (7.6)	
White	5634 (56.3)	740 (61.0)	568 (60.7)	172 (61.9)	
Prepregnancy BMI					0.04
Ν	9476	728	562	166	
Mean (SD)	27.5 (8.5)	28.2 (7.6)	27.5 (7.7)	30.4(6.7)	
BMI <19 kg/M ² [N, (%)]	403 (4.3)	32 (4.4)	28 (5)	4 (2.4)	0.85
Height (inches)					<0.001
N	9838	1033	797	236	
Mean (SD)	64.1 (2.7)	64.48 (2.69)	64.44 (2.69)	64.62 (2.7)	
Diabetes [N, (%)]	127 (1.3)	19 (1.6)	14 (1.5)	5 (1.8)	0.42
Opioid Use [N, (%)]	242 (2.4)	13 (1.1)	11 (1.2)	2 (0.7)	0
Hypertension [N, (%)]	606 (6.1)	105 (8.6)	72 (7.7)	33 (11.9)	<0.001
Smoking [N, (%)]	709 (7.8)	100 (9.5)	70 (8.6)	30 (12.3)	0.06
Insurance type [N, (%)]		· · · · · ·	· · · · · · · · · · · · · · · · · · ·		0.67
Government	2969 (29.7)	315 (28.6)	244 (28.5)	71 (28.6)	
Other	19 (0.2)	1 (0.1)	1 (0.1)	0 (0)	
Private	7012 (70.1)	787 (71.4)	610 (71.3)	177 (71.4)	
Delivery type [N, (%)]	. ()	,		<u> </u>	<0.001
Dilation & evacuation	0 (0.0)	1 (0.1)	0 (0.0)	1 (0.2)	
Primary cesarean delivery	1577 (15.8)	283 (20.2)	164 (17.9)	119 (24.5)	
Repeat cesarean deliverv	1541 (15.4)	177 (12.6)	119 (13.0)	58 (12.0)	
Vaginal deliverv	6630 (66.3)	923 (65.8)	624 (68)	299 (61.6)	
Vaginal delivery after cesarean	252 (2.5)	18 (1.3)	10 (1 1)	8 (1 6)	
. aginal acintory altor occarean	202 (2.0)	10 (1.0)		0 (1.0)	l

495 *P*-value reflects comparison of prospective vs historical arm.

496 [‡]Race is based on self-report.

497 BMI, body mass index.

498 Table 2: Results of hypothesis tests for the co-primary and co-secondary

499 outcomes using prespecified covariates

Co-primary endpoints				
		Lower	Upper	
	Hazard	confidence	confidence	_
Neonatal length of hospital stay [†]	ratio	limit	limit	P-value
Study arm prospective	1.35	1.08	1.70	0.01
Parous or nulliparous	0.94	0.82	1.08	0.39
Age	1.00	0.99	1.01	0.75
Opioid use	1.53	1.30	1.79	<0.001
		Lower	Upper	
		confidence	confidence	
Neonatal morbidity index [‡]	Odds ratio	limit	limit	<i>P</i> -value
Study arm prospective	0.81	0.67	0.98	0.03
Parous or nulliparous	0.58	0.52	0.65	0
Age	1.01	1.00	1.02	0.13
Opioid use	2.62	1.97	3.45	<0.001
Co-secondary endpoints				
		Lower	Upper	
	Hazard	confidence	confidence	
Neonatal intensive care unit length of stay [†]	ratio	limit	limit	<i>P</i> -value
Study arm prospective	1.20	0.96	1.51	0.12
Parous or nulliparous	0.96	0.84	1.10	0.57
Age	1.00	0.99	1.01	0.78
Opioid use	2.36	1.71	3.27	<0.001
		Lower	Upper	
	Hazard	confidence	confidence	
Gestational age (weeks)	ratio	limit	limit	<i>P</i> -value
Study arm	0.96	0.84	1.10	0.58
Parous or nulliparous	0.85	0.77	0.93	<0.001
Age	1.00	0.99	1.01	0.93
Opioid use	0.91	0.73	1.14	0.41

500 The co-primary and co-secondary outcomes included subjects in the upper 8.5%

501 quantile of neonatal length of stay, neonatal morbidity index score, and neonatal

502 intensive care unit length of stay within each arm, so that the large proportion of normal

503 births would not dilute the differences between arms.

- 504 [†]Cox regression analysis
- 505 [‡]Ordinal logistic regression analysis

506 Figure 1. Consort diagram for study inclusion



509 Figure 2: Kaplan-Meier curves for neonatal hospital length of stay



511 Figure 3: Kaplan-Meier curves for gestational age (weeks) for babies born <32

512 weeks' gestation



513

514 Figure 4: Kaplan-Meier curves for neonatal length of hospital stay (days) for

515 babies born <32 weeks' gestation



516

517

518 Supplementary Table 1. Comparison of probabilities of NMI levels and percent

519 differences in probabilities between arms for a range of co-variate values.

											Percent reduc Prospective a	tion in risks in rm relative to
						Predicted pro	babilities of N	MI categories			Control arm	
Arm	Multiparous	Age	Opioid Use	NMI = 0	NMI = 1	NMI = 2	NMI = 3	NMI = 4	NMI >= 3	NMI >= 1	NMI >= 3	NMI >= 1
Historical	NO	30	NO	0.831	0.082	0.055	0.024	0.009	0.033	0.169		
Prospective	No	30	No	0.858	0.069	0.045	0.020	0.007	0.027	0.142	18.47%	16.29%
Historical	Yes	30	No	0.894	0.053	0.034	0.014	0.005	0.020	0.106		
Prospective	Yes	30	No	0.912	0.044	0.028	0.012	0.004	0.016	0.088	18.68%	17.32%
Historical	No	30	Yes	0.652	0.147	0.119	0.060	0.022	0.082	0.348		
Prospective	No	30	Yes	0.698	0.132	0.102	0.050	0.018	0.068	0.302	17.69%	13.24%
Historical	Yes	30	Yes	0.763	0.109	0.078	0.036	0.013	0.050	0.237		
Prospective	Yes	30	Yes	0.799	0.095	0.066	0.030	0.011	0.041	0.201	18.21%	15.16%
Historical	No	20	No	0.842	0.077	0.051	0.023	0.008	0.031	0.158		
Prospective	No	20	No	0.868	0.065	0.042	0.018	0.006	0.025	0.132	18.51%	16.47%
Historical	Yes	20	No	0.901	0.049	0.031	0.013	0.005	0.018	0.099		
Prospective	Yes	20	No	0.919	0.041	0.026	0.011	0.004	0.015	0.081	18.70%	17.44%
Historical	No	20	Yes	0.670	0.141	0.113	0.056	0.021	0.076	0.330		
Prospective	No	20	Yes	0.715	0.127	0.096	0.046	0.017	0.063	0.285	17.79%	13.56%
Historical	Yes	20	Yes	0.777	0.103	0.073	0.034	0.012	0.046	0.223		
Prospective	Yes	20	Yes	0.812	0.090	0.061	0.028	0.010	0.038	0.188	18.27%	15.40%
Historical	No	40	No	0.819	0.087	0.059	0.026	0.009	0.036	0.181		
Prospective	No	40	No	0.848	0.074	0.049	0.022	0.008	0.029	0.152	18.43%	16.10%
Historical	Yes	40	No	0.886	0.057	0.036	0.016	0.005	0.021	0.114		
Prospective	Yes	40	No	0.906	0.047	0.030	0.013	0.004	0.017	0.094	18.65%	17.19%
Historical	No	40	Yes	0.633	0.152	0.126	0.065	0.024	0.089	0.367		
Prospective	No	40	Yes	0.680	0.138	0.109	0.053	0.020	0.073	0.320	17.59%	12.91%
Historical	Yes	40	Yes	0.748	0.115	0.084	0.039	0.014	0.054	0.252		
Prospective	Yes	40	Yes	0.785	0.100	0.070	0.032	0.012	0.044	0.215	18.15%	14.91%

NMI, neonatal morbidity index